PMID- 30133549
OWN - NLM
STAT- MEDLINE
DCOM- 20180906
LR  - 20181114
IS  - 1678-8060 (Electronic)
IS  - 0074-0276 (Print)
IS  - 0074-0276 (Linking)
VI  - 113
IP  - 10
DP  - 2018 Aug 20
TI  - Prognostic value of serum brain-derived neurotrophic factor levels in patients 
      with Chagas cardiomyopathy.
PG  - e180224
LID - S0074-02762018001000300 [pii]
LID - 10.1590/0074-02760180224 [doi]
LID - e180224
AB  - BACKGROUND: Serum brain-derived neurotrophic factor (BDNF) levels have been shown 
      to be lower in patients with Chagas cardiomyopathy (ChC) than in patients with 
      non-dilated chagasic cardiomyopathy. However, its prognostic value was not 
      established in patients with ChC. METHODS: Forty-nine patients with ChC (50 +/- 7 
      years, New York Heart Association "NYHA" I-III); were evaluated by 
      echocardiography, exercise testing, and blood analysis. Serum BDNF levels were 
      determined using enzyme-linked immunosorbent assay sandwich. Patients were 
      followed-up, and cardiac death was considered the end-point. The survival 
      analyses were performed using Kaplan-Meier and Cox regression. RESULTS: After 39 
      +/- 14 months of follow-up, 12 patients (25%) died. The concentration of 2.5 ng/mL 
      was the optimal cut-off value to predict survival with significant difference 
      between the groups with low (</= 2.5 ng/mL) and high (> 2.5 ng/mL) BDNF levels (p = 
      0.006). Lower serum BDNF levels (hazards ratio (HR) 1.1, 95% confidence interval 
      (CI) 1.1-1.4; p = 0.001), peak oxygen uptake (HR 1.2, 95% CI 1.0-1.3; p = 0.009), 
      and left ventricular ejection fraction (HR 0.8, 95% CI 0.7-0.9; p = 0.001) were 
      the independent predictors of survival. The combination of low serum BDNF levels 
      and reduced left ventricular ejection fraction were highly predictive of death 
      (HR 5.6, 95% CI: 1.2-9.7; p = 0.026). CONCLUSION: In patients with ChC, reduced 
      serum BDNF levels, especially if associated with systolic function, may provide 
      useful prognostic information.
FAU - Costa, Henrique S
AU  - Costa HS
AD  - Universidade Federal de Minas Gerais, Departamento de Clinica Medica, Curso de 
      Pos-Graduacao em Infectologia e Medicina Tropical, Belo Horizonte, MG, Brasil.
FAU - Lima, Marcia Maria O
AU  - Lima MMO
AD  - Universidade Federal dos Vales do Jequitinhonha e Mucuri, Faculdade de Ciencias 
      Biologicas e da Saude, Departamento de Fisioterapia, Diamantina, MG, Brasil.
FAU - Figueiredo, Pedro Henrique S
AU  - Figueiredo PHS
AD  - Universidade Federal dos Vales do Jequitinhonha e Mucuri, Faculdade de Ciencias 
      Biologicas e da Saude, Departamento de Fisioterapia, Diamantina, MG, Brasil.
FAU - Martinelli, Patricia M
AU  - Martinelli PM
AD  - Universidade Federal de Minas Gerais, Instituto de Ciencias Biologicas, 
      Departamento de Morfologia, Belo Horizonte, MG, Brasil.
FAU - Camargos, Elizabeth Rs
AU  - Camargos ER
AD  - Universidade Federal de Minas Gerais, Instituto de Ciencias Biologicas, 
      Departamento de Morfologia, Belo Horizonte, MG, Brasil.
FAU - Chaves, Ana Thereza
AU  - Chaves AT
AD  - Universidade Federal de Minas Gerais, Departamento de Clinica Medica, Curso de 
      Pos-Graduacao em Infectologia e Medicina Tropical, Belo Horizonte, MG, Brasil.
FAU - Nunes, Maria Carmo Pereira
AU  - Nunes MCP
AD  - Universidade Federal de Minas Gerais, Departamento de Clinica Medica, Curso de 
      Pos-Graduacao em Infectologia e Medicina Tropical, Belo Horizonte, MG, Brasil.
FAU - Rocha, Manoel Otavio C
AU  - Rocha MOC
AD  - Universidade Federal de Minas Gerais, Departamento de Clinica Medica, Curso de 
      Pos-Graduacao em Infectologia e Medicina Tropical, Belo Horizonte, MG, Brasil.
LA  - eng
PT  - Journal Article
DEP - 20180820
PL  - Brazil
TA  - Mem Inst Oswaldo Cruz
JT  - Memorias do Instituto Oswaldo Cruz
JID - 7502619
RN  - 0 (Brain-Derived Neurotrophic Factor)
SB  - IM
MH  - Adult
MH  - Brain-Derived Neurotrophic Factor/*blood
MH  - Chagas Cardiomyopathy/*blood/physiopathology
MH  - Echocardiography
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Exercise Test
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Failure/blood/physiopathology
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Oxygen Consumption/physiology
MH  - Prognosis
MH  - Prospective Studies
MH  - Reference Standards
MH  - Risk Assessment/methods
MH  - Risk Factors
MH  - Sensitivity and Specificity
MH  - Statistics, Nonparametric
MH  - Stroke Volume/physiology
MH  - Time Factors
PMC - PMC6107101
EDAT- 2018/08/23 06:00
MHDA- 2018/09/07 06:00
PMCR- 2018/08/20
CRDT- 2018/08/23 06:00
PHST- 2018/05/01 00:00 [received]
PHST- 2018/08/03 00:00 [accepted]
PHST- 2018/08/23 06:00 [entrez]
PHST- 2018/08/23 06:00 [pubmed]
PHST- 2018/09/07 06:00 [medline]
PHST- 2018/08/20 00:00 [pmc-release]
AID - S0074-02762018001000300 [pii]
AID - 10.1590/0074-02760180224 [doi]
PST - epublish
SO  - Mem Inst Oswaldo Cruz. 2018 Aug 20;113(10):e180224. doi: 
      10.1590/0074-02760180224.